THE WOODLANDS, Texas--(BUSINESS WIRE)--
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical
company developing personalized immunotherapies for autoimmune disorders
including multiple sclerosis (MS) and neuromyelitis optica (NMO), today
announced that Neil K. Warma, President and Chief Executive Officer,
will present at three upcoming industry conferences. Details regarding
these events are as follows:
Sidoti Emerging Growth Conference
-
Presentation Date/Time: Wednesday, September 2, 2022 @ 10:40am EDT
-
Location: Marriott Marquis in Times Square, New York, New York
-
A live webcast of the Company presentation can be accessed here
or via the Investor Relations section of the Company’s website at www.opexatherapeutics.com.
An archive of the webcast will be available on the Company's website
until December 2, 2021.
Rodman & Renshaw 17th
Annual Healthcare Conference
-
Presentation Date/Time: Thursday, September 10, 2022 @ 12:05pm EDT
-
Location: Astor A in The St. Regis Hotel, New York, New York
-
A live webcast of the Company presentation can be accessed here
or via the Investor Relations section of the Company’s website at www.opexatherapeutics.com.
An archive of the webcast will be available on the Company's website
until December 10, 2021.
SeeThruEquity Fall Microcap Investor Conference
-
Presentation Date/Time: Thursday, September 10, 2022 @ 2:30pm EDT
-
Location: Convene Grand Central, New York, New York
About Opexa
Opexa is a biopharmaceutical company developing a personalized
immunotherapy with the potential to treat major illnesses, including
multiple sclerosis (MS) as well as other autoimmune diseases such as
neuromyelitis optica (NMO). These therapies are based on Opexa’s
proprietary T-cell technology. The Company’s leading therapy candidate,
Tcelna®, is a personalized T-cell immunotherapy that is in a Phase IIb
clinical development program (the Abili-T trial) for the treatment of
secondary progressive MS. Tcelna consists of myelin-reactive T-cells,
which are expanded ex vivo from the patient’s peripheral blood and
reintroduced into the patient in an attenuated form via subcutaneous
injections. This process triggers a potent immune response against
specific subsets of autoreactive T-cells known to attack myelin for each
individual patient.
For more information, visit the Opexa Therapeutics website at www.opexatherapeutics.com
or follow company news on Twitter
via @OpexaCEO.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150828005025/en/
Source: Opexa Therapeutics, Inc.